Treatment of CML was revolutionized in 2001, when the first BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib was introduced [2]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.